Nano-hydroxyapatite vs hydroxyapatite

Nano-hydroxyapatite and hydroxyapatite are the same mineral. The difference is particle size—and, for regulators, particle shape.

That distinction matters more than marketing copy usually admits. “Nano” on a toothpaste label is not a separate ingredient name, a guarantee of better clinical results, or a synonym for “unsafe.” It is a size (and, in Europe, a regulated morphology) claim.

Same chemistry, different scale

Hydroxyapatite is a calcium phosphate mineral with the stoichiometric formula Ca₁₀(PO₄)₆(OH)₂. Synthetic versions of that mineral are used in toothpaste as a biomimetic enamel ingredient.

Nano-hydroxyapatite (nHA / n-HAP) means particles with at least one dimension in the nanometre range. Under common EU cosmetics nanomaterial framing, that is conventionally 1–100 nm. In oral-care literature and marketing, commercial nHA is often described as roughly 20–100 nm, frequently rod-shaped, intended to approximate enamel crystallite dimensions.

Microcrystalline hydroxyapatite is the same chemistry at a larger particle size—often summarised in secondary reviews as a few micrometres (for example, roughly 5–10 µm). That is still “small” in everyday terms, but it is not nano.

Typical sizes and shapes

One SCCS dossier example (nanoXIM CarePaste) reported median length about 28 nm and median width about 15 nm, rod-shaped. Submission IV discussion of assessed material cited a maximum length around 122 ± 43 nm for the characterised nano grade under review.

Aspect ratio (length divided by width) matters in Europe. The 2023 SCCS opinion required rod-shaped particles with tight aspect-ratio limits and no coating or surface modification. Needle-shaped particles were excluded from the safe conclusion.

Why particle size is discussed at all

Smaller particles have higher surface area. In principle, that can mean:

1. Better access to microscopic enamel defects and early lesion porosity.
2. Better potential to enter and occlude open dentinal tubules (a sensitivity mechanism).
3. Different deposition behaviour on the enamel surface during brushing.

Laboratory and in-situ remineralisation work often uses nano grades for that reason. Dose-response work such as Huang et al. (2009) studied nano-HA concentrations in vitro; Najibfard et al. (2011) compared 5% and 10% nano-HA in situ and found both remineralised early lesions, with no significant difference between those two concentrations for mineral gain in that protocol.

That is useful mechanistic evidence. It is not the same as proving nano toothpaste beats micro toothpaste in everyday cavity prevention.

Remineralisation narrative vs clinical endpoints

Writers and brands sometimes slide from “nano particles fit enamel defects in SEM images” to “nano prevents more cavities.” Those are different claims.

• In vitro: surface microhardness recovery, mineral gain on artificial lesions, and visible surface deposits are comparatively easy to show.
• In situ: short windows with enamel slabs worn in the mouth can show mineral changes under more realistic saliva and plaque conditions—still usually small samples and short duration.
• Clinical caries endpoints: need randomised trials measuring new lesions or DMFS-type outcomes over months to years. That is where microcrystalline 10% HA currently has the clearer published trail.

A paste can be excellent at leaving a mineral film under a microscope and still lack a head-to-head clinical win for nano versus micro.

Sensitivity is a separate question

Tubule occlusion is one place where smaller particles are especially plausible. Open dentinal tubules are micrometre-scale openings; particles that can enter and plug them reduce fluid flow linked to sharp pain. HA sensitivity meta-analyses support meaningful clinical reductions for HA-containing products as a class—but those analyses pool products and do not settle “nano always beats micro for sensitivity” as a universal rule.

If sensitivity is your main goal, judge the product’s clinical citations and your caries risk together, not the word “nano” alone.

What the caries trials actually used

This is where label language and trial language diverge.

Several of the best-known hydroxyapatite caries non-inferiority trials tested 10% microcrystalline HA, not a marketed “nano” paste:

• Schlagenhauf et al., 2019 — orthodontic patients; fluoride-free 10% microcrystalline HA vs a fluoride control.
• Paszynska et al., 2021 — children aged 3–7; 10% microcrystalline HA vs 500 ppm amine fluoride.
• Paszynska et al., 2023 — adults; 10% HA vs 1,450 ppm sodium fluoride.

If a brand advertises “nano” while citing those trials, the citation is about hydroxyapatite as an active class, not proof that the brand’s nano fraction drove the result.

What EU regulators mean by “nano”

In the European Union, nano-HA in cosmetics is a regulated nanomaterial. Two scientific milestones matter for readers:

SCCS/1648/22 (final March 2023): nano-HA considered safe at up to 10% in toothpaste and 0.465% in mouthwash, only for specified rod-shaped, largely low-aspect-ratio, uncoated particles—not needle-shaped, not sprayable products with inhalation risk. Quantitatively, the opinion required at least 95.8% of particles (by number) with aspect ratio below 3, with the remaining at most 4.2% at aspect ratio up to 4.9.

Commission Regulation (EU) 2024/858 translates that conclusion into Annex III restrictions for hydroxyapatite (nano), with applicability dates for non-compliant products rolling through 2025.

SCCS Submission IV (2025) later supported higher scientific ceilings (up to 29.5% toothpaste / 10% mouthwash) for characterised rod-shaped materials meeting updated aspect-ratio and length criteria (at least 87% of particles with aspect ratio of 3 or less; remaining at most 13% with aspect ratio of 9 or less; assessed max length 122 ± 43 nm). Whether cosmetics law has been fully amended to match those higher ceilings should be verified on EUR-Lex before anyone treats 29.5% as the current legal maximum EU-wide.

Rationale highlights from the newer opinion include negligible mucosal uptake concerns for the assessed materials and dissolution of ingested particles in gastric fluid—i.e., nano-specific systemic risk was not the driver of the limits; morphology and exposure route were.

For a fuller safety walkthrough, see Is hydroxyapatite toothpaste safe?.

Marketing language that muddies the water

A few patterns show up repeatedly:

“Medical-grade nano.” Sounds rigorous; usually undefined. Prefer disclosed % HA, particle characterisation, and named trials.

“Identical to natural enamel.” Biological enamel mineral is carbonated, defective, poorly crystalline apatite—not pure stoichiometric HA. Synthetic toothpaste HA is chemically similar / biomimetic, not identical. See the hydroxyapatite primer.

“NASA nano toothpaste.” NASA patented a crystal-growth repair concept; Japanese company Sangi commercialised particulate HA toothpaste (Apadent 1980; Apagard 1985). History matters, but it does not prove a modern nano grade is clinically superior. Timeline details: Japanese history of HA toothpaste.

“Nano is banned in the EU.” False. Specified rod-shaped nano-HA is restricted and conditioned—not blanket-banned.

How to read “nano” on a toothpaste label

Useful questions when comparing products:

1. Does the brand disclose concentration? Research and premium retail levels often cluster at 5% or 10%. See how much hydroxyapatite you need.
2. Does it say nano, micro, or both? Blends exist. Disclosure quality varies.
3. Is the brand citing microcrystalline trials for a nano claim? Related, but not identical.
4. Are safety claims morphology-specific? Honest copy mentions rods, coatings, and concentration limits—not a blanket “nano is cleared.”
5. Is “nano” doing scientific work or shelf work? If the only differentiator is the word itself, keep reading.

A note on blends

Some formulas—including products that list “nano & micro”—intentionally mix sizes. The idea is coverage across surface deposition and smaller-defect access. That can be a coherent formulation strategy. It still does not invent missing morphology data or create a clinical superiority claim without trials.

Substituted grades complicate the picture further

Not every “HA toothpaste” is stoichiometric micro or classic nHA. Some European formulas use carbonate-substituted or zinc-carbonate HA systems with different surface chemistry and, sometimes, very different mineral loadings on the label. Those products are related biomimetic approaches, not interchangeable with every nHA study.

Zinc is sometimes argued to limit particle aggregation at higher loadings and to add mild antimicrobial or anti-calculus effects. That may be true for specific systems; it is not a free upgrade you can assume for every “HA” SKU.

For buying criteria beyond particle buzzwords, see the hydroxyapatite toothpaste buyer’s guide.

Who should care about nano vs micro?

Care more if: you are evaluating EU safety claims, comparing SEM/mechanism papers, or a brand’s marketing hinges on “nano” as the reason to pay more.

Care less if: you mainly want a studied HA concentration with transparent labelling, and the brand’s citations match a microcrystalline clinical programme.

Either way, particle grade is one variable among concentration, abrasivity, co-ingredients, and your caries risk—not a master key.

Bottom line

Nano-hydroxyapatite is hydroxyapatite at a smaller particle size. That size difference is real, regulated in Europe, and mechanistically interesting. It is not, by itself, proof of a better toothpaste.

If you are choosing between pastes, weigh disclosed concentration, the rest of the formula, abrasivity, and whether the brand’s citations match the particle grade it sells. For cavity-prevention evidence specifically, follow the clinical trial summaries rather than the word “nano” on the tube.